Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: Relations to angiographically verified severity of coronary artery disease

Atherosclerosis

Volumn 150, Issue 1, 2000, Pages 167-177

  Mero, N ^a   Malmstrom R ^a   Steiner, G ^b,c   Taskinen, M R ^a   Syvanne M ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c DAIS Project Group   (Canada)

Author keywords

Apolipoprotein B 100; Apolipoprotein B 48; Apolipoprotein E phenotype; Atherosclerosis; Postprandial lipemia; Quantitative coronary angiography; Triglyceride rich lipoproteins; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CHYLOMICRON; LIPID; LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DENSITY GRADIENT CENTRIFUGATION; FAT INTAKE; FEMALE; HUMAN; INTESTINE; LIVER; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RADIOGRAPHY;

ADULT; AGED; APOLIPOPROTEIN B-100; APOLIPOPROTEIN B-48; APOLIPOPROTEINS B; CENTRIFUGATION, DENSITY GRADIENT; CHYLOMICRONS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIETARY FATS; FEMALE; HUMANS; INTESTINES; LIPIDS; LIPOPROTEINS; LIVER; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 0034181352     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00364-0     Document Type: Article

References (61)

1. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974;23:105-11.
2. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB. Mortality among diabetics in a national sample. Am J Epidemiol 1988;128:389-401.
3. Koskinen P, Mänttäri M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820-5.
4. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
5. Taskinen MR, Lahdenperä S, Syvänne M. New insights into lipid metabolism in non-insulin-dependent diabetes mellitus. Ann Med 1996;28:335-40.
6. Laakso M, Lehto S, Penttilä I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin dependent diabetes. Circulation 1993;88:1421-30.
7. Hanefeld M, Fischer S, Julius U, Schutze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-83.
8. Chen YD, Swami S, Skowronski R, Coulston A, Reaven GM. Differences in postprandial lipemia between patients with normal glucose tolerance and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993;76:172-7.
9. Lewis GF, O'Meara NM, Soltys PA, Blackman JD, Iverius PH, Pugh WL, Getz GS, Polonsky KS. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 1991;72:934-44.
10. Syvänne M, Vuorinen-Markkola H, Hilden H, Taskinen MR. Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 1993;13:286-95.
11. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-85.
12. Groot PH, van Stiphout WA, Krauss XH, Jansen H, van Tol A, van Ramshorst E, Chin-On S, Hofman A, Cresswell SR, Havekes L. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 1991;11:653-62.
13. Patsch J, Miesenböck G, Hopferwieser T, Muhlberger V, Knapp E, Dunn J, Gotto A Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992;12:1336-45.
14. Weintraub MS, Grosskopf I, Rassin T, Miller H, Charach G, Rotmensch HH, Liron M, Rubinstein A, Iaina A. Clearance of chylomicron remnants in normolipidemic patients with coronary artery disease: case control study over three years. Br Med J 1996;312:935-9.
15. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994;106:83-97.
16. Ebenbichler CF, Kirchmair R, Egger C, Patsch JR. Postprandial state and atherosclerosis. Curr Opin Lipidol 1995;6:286-90.
17. Karpe F, Hamsten A. Postprandial lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 1995;6:123-9.
18. Lefebvre PJ, Scheen AJ. The postprandial state and risk of cardiovascular disease. Diabetic Med 1998;15:S63-8.
19. De Man FHAF, Castro Cabezas M, Van Barlingen HHJJ, Erkelens DW, De Bruin TWA. Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest 1996;26:89-108.
20. Coppack SW. Postprandial lipoproteins in non-insulin-dependent diabetes mellitus. Diabetic Med 1997;14:S67-74.
21. Tkác I, Kimball BK, Lewis G, Uffelman K, Steiner G. The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. Arterioscler Thromb Vasc Biol 1997;17:3633-8.
22. Syvänne M, Hilden H, Taskinen MR. Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease. J Lipid Res 1994;35:15-26.
23. Kirchmair R, Ebenbichler CF, Patsch JR. Post-prandial lipaemia. Baillieres Clin Endocrinol Metab 1995;9:705-19.
24. Steiner G. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. Diabetologia 1996;39:1655-61.
25. Mero N, Syvänne M, Rosseneu M, Labeur C, Hilden H, Taskinen M-R. Comparison of three fatty meals in healthy normolipidemic men: high post-prandial retinyl ester response to soybean oil. Eur J Clin Invest 1998;28:407-15.
26. McLaughlin PR, Gladstone P. Diabetes Atherosclerosis Intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis. Cathet Cardiol Diag 1998;44:249-56.
27. Karpe F, Hamsten A. Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. J Lipid Res 1994;35:1311-7.
28. Huttunen JK, Ehnholm C, Kinnunen PKJ, Nikkilä EA. An immunochemical method for selective measurement of two triglyceride lipases in human postheparin plasma. Clin Chim Acta 1975;63:335-47.
29. Ruotolo G, Huizhen Z, Bentsianov V, Ngoc-Anh L. Protocol for the study of the metabolism of retinyl esters in plasma lipoproteins during postprandial lipemia. J Lipid Res 1992;33:1541-9.
30. Havekes LM, de Knijff P, Beisiegel U, Havinga J, Smith M, Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 1987;28:455-63.
31. Ludbrook J. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc Res 1994;28:303-11.
32. Matthews J, Altman D, Campbell M, Royston P. Analysis of serial measurements in medical research. Br Med J 1990;300:230-5.
33. Cavallero E, Dachet C, Neufcour D, Wirquin E, Mathe D, Jacotot B. Postprandial amplification of lipoprotein abnormalities in controlled type II diabetic subjects: relationship to postprandial lipemia and C-peptide/glucagon levels. Metabolism 1994;43:270-8.
34. Curtin A, Deegan P, Owens D, Collins P, Johnson A, Tomkin GH. Alterations in apolipoprotein B-48 in the postprandial state in NIDDM. Diabetologia 1994;37:1259-64.
35. Mahnström R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Järvinen H, Shepherd J, Taskinen M-R. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997;40:454-62.
36. Chen YD, Golay A, Swislocki AL, Reaven GM. Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987;64:17-21.
37. Swislocki AL, Chen YD, Golay A, Chang MO, Reaven GM. Insulin suppression of plasma-free fatty acid concentration in normal individuals and patients with type 2 (non-insulin-dependent) diabetes. Diabetologia 1987;30:622-6.
38. Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 1994;5:102-9.
39. Brunzell JD, Porte D Jr, Bierman EL. Reversible abnormalities in postheparin lipolytic activity during the late phase of release in diabetes mellitus (postheparin lipolytic activity in diabetes). Metabolism 1975;24:1123-37.
40. Nikkilä EA, Huttunen JK, Ehnhohn C. Postheparin plasma lipoprotein lipase and hepatic lipase in diabetes mellitus. Relationship to plasma triglyceride metabolism. Diabetes 1977;26:11-21.
41. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res 1997;38:2173-92.
42. Beisiegel U, Weber W, Bengtsson Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci USA 1991;88:8342-6.
43. Curtiss LK, Witztum JL. Plasma apolipoproteins AI, AII, B, CI, and E are glucosylated in hyperglycemic diabetic subjects. Diabetes 1985;34:452-61.
44. Mamo JC, Szeto L, Steiner G. Glycation of very low density lipoprotein from rat plasma impairs its catabolism. Diabetologia 1990;33:339-45.
45. Karpe F, de Faire U, Mercuri M, Bond MG, Hellenius ML, Hamsten A. Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middleaged men. Atherosclerosis 1998;141:307-14.
46. Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, Poonia NS, Balasubramaniam S, Baron D, Branson J, Morgan J, et al. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis 1987;65:181-9.
47. Simpson HS, Williamson CM, Olivecrona T, Pringle S, Maclean J, Lorimer AR, Bonnefous F, Bogaievsky Y, Packard CJ, Shepherd J. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis 1990;85:193-202.
48. Meyer E, Westerveld HT, de Ruyter-Meijstek FC, van Greevenbroek MM, Rienks R, van Rijn HJ, Erkelens DW, de Bruin TW. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study. Atherosclerosis 1996;124:221-35.
49. Sherrill BC, Innerarity TL, Mahley RW. Rapid hepatic clearance of the canine lipoproteins containing only the E apoprotein by a high affinity receptor. Identity with the chylomicron remnant transport process. J Biol Chem 1980;255:1804-7.
50. Syvänne M, Rosseneu M, Labeur C, Hilden H, Taskinen MR. Enrichment with apolipoprotein E characterizes postprandial TG-rich lipoproteins in patients with non-insulin-dependent diabetes mellitus and coronary artery disease: a preliminary report. Atherosclerosis 1994;105:25-34.
51. Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease: A mela-analysis. Arterioscler Thromb Vasc Biol 1996;16:1250-5.
52. Weintraub MS, Eisenberg S, Breslow JL. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J Clin Invest 1987;80:1571-7.
53. Boerwinkle E, Brown S, Sharrett AR, Heiss G, Patsch W. Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. Am J Hum Genet 1994;54:341-60.
54. Bergeron N, Havel RJ. Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein epsilon4 allele. J Clin Invest 1996;97:65-72.
55. Reznik Y, Pousse P, Herrou M, Morello R, Mahoudeau J, Drosdowsky MA, Fradin S. Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin-dependent diabetic patients: influence of apolipoprotein E polymorphism. Metabolism 1996;45:63-71.
56. Syvänne M, Ahola M, Lahdenperä S, Kahri J, Kuusi T, Virtanen KS, Taskinen MR. High density lipoprotein subfractions in non-insuhn-dependent diabetes mellitus and coronary artery disease. J Lipid Res 1995;36:573-82.
57. Patsch JR, Prasad S, Gotto AMJ, Bengtsson-Olivecrona G. Postprandial lipemia. A key for the conversion of high density lipoprotein2 into high density lipoprotein 3 by hepatic lipase. J Clin Invest 1984;74:2017-23.
58. Karpe F, Bard JM, Steiner G, Carlson LA, Fruchart JC, Hamsten A. HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at a young age. Arterioscler Thromb 1993;13:11-22.
59. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
60. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B-12B.
61. Boquist S, Ruotolo G, Hellenius ML, Danell-Toverud K, Karpe F, Hamsten A. Effects of a cardioselective beta-blocker on postprandial triglyceride-rich lipoproteins, low density lipoprotein particle size and glucose-insulin homeostasis in middleaged men with modestly increased cardiovascular risk. Atherosclerosis 1998;137:391-400.